Investors
Share price
{{priceData.date}} {{priceData.time}}
{{'2024-03-08T18:42:10Z' | dateFormatFilter}}
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Read more
{{'2024-03-07T07:00:42Z' | dateFormatFilter}}
Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
Read more
{{'2024-03-05T09:53:48Z' | dateFormatFilter}}
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Read more
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.